The response to crizotinib or other ALK inhibitors is presently unknown, but preclinical studies have shown that R1275Q cell lines are sensitive to crizotinib (Bresler et al., 2014; Schonherr et al., 2011), and clinical trials investigating crizotinib in neuroblastoma are underway. This evidence concerns the gene ALK and neuroblastoma.